Antiproliferative and proapoptotic effect of the MLK/JNK inhibitor CEP-1347 in hepatocellular carcinoma
EN De Toni, S Lu, J Liebl, A Rizzani, B Göke, E Gallmeier, AM Vollmar, AL Gerbes · Zeitschrift für Gastroenterologie · 2014 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: Sorafenib is the only systemic agent approved for the therapy of hepatocellular carcinoma (HCC). However, in spite of its efficacy, the investigation of alternative therapeutic targets is urgently required. JNK is overexpressed in the majority of HCC and chemical induction of HCC is prevented by JNK inhibition. Notably, expression of JNK was recently shown to predict a poor response to sorafenib. Nevertheless, since no JNK inhibitor is currently undergoing investigation as therapy of HCC, JNK remains a largely unexploited therapeutic target. CEP-1347 is a MLK/JNK inhibitor originally designed to prev…
